Diurnal Group PLC Director Declaration (8584N)
11 May 2018 - 11:41PM
UK Regulatory
TIDMDNL
RNS Number : 8584N
Diurnal Group PLC
11 May 2018
11 May 2018
Diurnal Group plc
("Diurnal" or the "Company")
Director Declaration
Diurnal Group plc (AIM: DNL), the specialty pharmaceutical
company targeting patient needs in chronic endocrine (hormonal)
diseases, makes the following announcement pursuant to Schedule 2,
paragraph (g) and AIM Rule 17 of the AIM Rules for Companies. The
Company has been informed by Richard Bungay, Chief Financial
Officer of the Company, of the following changes to his director
details in respect of a directorship:
Mr Bungay was appointed a director of Glide Pharmaceutical
Technologies Limited ("Glide") on 1 July 2014. On 31 August 2017,
Lindsey Cooper and David Ronald Taylor of RSM Restructuring
Advisory LLP were appointed as joint administrators of Glide
Pharmaceutical Technologies Limited. A notice of progress report to
7 March 2018 and filed on 15 March 2018 indicated all unsecured
creditor balances had been settled. Due to an oversight, this
information was not reported to the Company at the time.
For further information, please visit www.diurnal.co.uk or contact:
Diurnal Group plc +44 (0)20 3727 1000
Martin Whitaker, Chief Executive Officer
Richard Bungay, Chief Financial Officer
Numis Securities Ltd (Nominated Adviser) +44 (0)20 7260 1000
Nominated Adviser: Michael Meade, Paul Gillam,
Freddie Barnfield
Corporate Broking: James Black
Panmure Gordon (UK) Limited (Joint Broker) +44 (0) 20 7886 2500
Corporate Finance: Freddy Crossley, Emma Earl
Corporate Broking: James Stearns
FTI Consulting (Investor Relations) +44 (0)20 3727 1000
Simon Conway
Victoria Foster Mitchell
Notes to Editors
About Diurnal Group plc
Founded in 2004, Diurnal is a UK-based specialty pharma company
developing high quality products for the global market for the
life-long treatment of chronic endocrine conditions, including
Congenital Adrenal Hyperplasia and Adrenal Insufficiency. Its
expertise and innovative research activities focus on
circadian-based endocrinology to yield novel product candidates in
the rare and chronic endocrine disease arena.
For further information about Diurnal, please visit
www.diurnal.co.uk
This information is provided by RNS
The company news service from the London Stock Exchange
END
RDNDMGMKFMGGRZM
(END) Dow Jones Newswires
May 11, 2018 09:41 ET (13:41 GMT)
Diurnal (LSE:DNL)
Historical Stock Chart
From Apr 2024 to May 2024
Diurnal (LSE:DNL)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Diurnal Group Plc (London Stock Exchange): 0 recent articles
More Diurnal Grp News Articles